Evidence map›Paper›PMID 38864697›Full record

ArticleEndocrine-related cancer2024

Genetic variants and down-regulation of CACNA1H in pheochromocytoma.

Fredrika Svahn, Karolina Solhusløkk Höse, Adam Stenman, Yaxuan Liu, Jan Calissendorff, Emma Tham, Ákos Végvári, Roman A Zubarev, Na Wang, Reju Korah and 5 more

Abstract read
In one paragraph

Article in Endocrine-related cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fredrika SvahnDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Karolina Solhusløkk HöseDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Adam StenmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3248-7629
Yaxuan LiuDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jan CalissendorffDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Emma ThamDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6079-164X
Ákos VégváriDivision of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Roman A ZubarevDivision of Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Na WangDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Reju KorahYale Endocrine Neoplasia Laboratory, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Tobias CarlingYale Endocrine Neoplasia Laboratory, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Jan ZedeniusDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Robert BränströmDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
C Christofer JuhlinDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-5945-9081
Catharina LarssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytoma (PCC) and abdominal paraganglioma (aPGL) (together abbreviated PPGL) frequently present with an underlying genetic event in a PPGL driver gene, and additional susceptibility genes are anticipated. Here, we re-analyzed whole-exome sequencing data for PCC patients and identified two patients with rare missense variants in the calcium voltage-gated channel subunit 1H gene (CACNA1H). CACNA1H variants were also found in the clinical setting in PCC patients using targeted sequencing and from analysis of The Cancer Genome Atlas database. In total, CACNA1H variants were found in six PCC cases. Three of these were constitutional, and two are known to have functional consequences on hormone production and gene expression in primary aldosteronism and aldosterone-producing adrenocortical adenoma. In general, PPGL exhibited reduced CACNA1H mRNA expression as compared to normal adrenal. Immunohistochemistry showed strong CACNA1H (CaV3.2) staining in adrenal medulla while PPGL typically had weak or negative staining. Reduced CACNA1H gene expression was especially pronounced in PCC compared to aPGL and in PPGL with cluster 2 kinase signaling phenotype. Furthermore, CACNA1H levels correlated with HIF1A and HIF2A. Moreover, TCGA data revealed a correlation between CACNA1H methylation density and gene expression. Expression of rCacna1h in PC12 cells induced differential protein expression profiles, determined by mass spectrometry, as well as a shift in the membrane potential where maximum calcium currents were observed, as determined by electrophysiology. The findings suggest the involvement of CACNA1H/CaV3.2 in pheochromocytoma development and establish a potential link between the etiology of adrenomedullary and adrenocortical tumor development.

Indexed as

Adrenal Gland NeoplasmsDown-RegulationPheochromocytomaAdultAnimalsCalcium Channels, T-TypeFemaleHumansMaleMiddle AgedPC12 CellsRatsCACNA1H protein, humanCalcium Channels, T-TypeCACNA1Hcalcium channelparagangliomapheochromocytoma

Identifiers

PMID38864697
PMCPMC11301417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.